| | Business Summary | | Peregrine
Pharmaceuticals,
Inc.
is
a
biopharmaceutical
company
engaged
in
the
development
and
commercialization
of
cancer
therapeutics
and
cancer
diagnostics
through
a
series
of
proprietary
platform
technologies
using
monoclonal
antibodies.
Peregrine's
main
focus
is
on
the
development
of
its
Collateral
Targeting
Agent
technologies.
In
addition
to
Collateral
Targeting
Agents,
the
Company
has
a
direct
tumor-targeting
agent,
Oncolym,
for
the
treatment
of
Non-Hodgkins
B-cell
Lymphoma
(NHL).
The
Oncolym
antibody
is
linked
to
a
radioactive
isotope
(131I)
and
the
combined
molecule
is
injected
into
the
blood
stream
of
the
lymphoma
patient,
where
it
recognizes
and
binds
to
the
cancerous
lymphoma
tumor
sites,
thereby
delivering
the
radioactive
isotope
directly
to
the
tumor
site. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | Peregrine
Pharmaceuticals
is
a
biopharmaceutical
co.
engaged
in
the
research,
development
and
commercialization
of
targeted
cancer
therapeutics,
utilizing
proprietary
collateral
tumor
targeting
technologies.
For
the
fiscal
year
ended
4/01,
revenue
totaled
$979
thousand,
up
from
$50
thousand.
Net
loss
applicable
to
Common
fell
34%
to
$9.5
million.
Revenues
reflect
increase
in
license
revenue
from
licensing
collaborations.
Lower
loss
reflects
the
absence
of
$1.3
million
in
note
receivable
expenses. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Edward Legere, ll, 37
Pres,
CEO, Director | -- | -- | Paul Lytle, 32
VP,
Fin. & Accounting and Corp. Sec. | $131K | $405K | Terrence Chew, M.D., 53
VP
of Clinical and Regulatory Affairs | 135K | 685K | Steve King, 36
VP,
Technology & Product Devel. | 149K | 461K | | Dollar
amounts are as of 30-Apr-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/p/pphm.gif)